12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study
| Autor: | Reinmuth, N., Cho, B.C., Luft, A., Alexander, J.A. Alatorre, Geater, S. Lucien, Laktionov, K., Kim, S-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C-T., Araujo, L.H., Saito, H., Barrett, K., Lowery, C., Tattersfield, R., Peters, S., Garon, E.B., Mok, T.S.K., Johnson, M.L. |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology April 2023 18(4) Supplement:S44-S46 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|